SinoMab BioScience Ltd
Company Profile
Business description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Contact
No. 15 Science Park West Avenue
Units 303 and 305 to 307
Hong Kong Science Park, Pak Shek Kok
New Territories
Hong Kong
HKGT: +852 34269833
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
61
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
Tesla earnings: Shares fall as market focuses on uncertainty in near term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,329.10 | 14.60 | -0.16% |
| CAC 40 | 8,225.78 | 18.91 | 0.23% |
| DAX 40 | 24,207.79 | 56.66 | 0.23% |
| Dow JONES (US) | 46,734.61 | 144.20 | 0.31% |
| FTSE 100 | 9,578.57 | 63.57 | 0.67% |
| HKSE | 26,090.13 | 122.15 | 0.47% |
| NASDAQ | 22,941.80 | 201.40 | 0.89% |
| Nikkei 225 | 49,299.12 | 657.51 | 1.35% |
| NZX 50 Index | 13,410.93 | 33.83 | 0.25% |
| S&P 500 | 6,738.44 | 39.04 | 0.58% |
| S&P/ASX 200 | 9,029.10 | 15.10 | -0.17% |
| SSE Composite Index | 3,933.41 | 11.00 | 0.28% |